Porscha Johnson Williams, Senior Oncology Medical Science Liaison at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“I’m still in utter disbelief!! Our study was just published in JCO Precision Oncology!!
To our knowledge, this is the first large-scale study to evaluate germline PGx variants in the context of therapeutically actionable somatic mutations, defining their combined landscape of clinical actionability.
Honored to contribute alongside a world renowned team of expert co-authors! An insurmountable amount of gratitude to Vai Pathak, Courtney Hershberger, Suneel Kamath, Terence Rhodes, Howard McLeod, and Daniel Rotroff for their collaboration, insights, and dedication.
Key Takeaway: Integrated somatic and germline pharmacogenomics shows that actionable germline variants are virtually universal in cancer patients and often exceed somatic targets, highlighting the potential to tailor drug dosing, toxicity risk, and supportive care alongside tumor-directed therapies to advance truly comprehensive precision oncology.”
Title: Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology
Authors: Vai Pathak, Courtney Hershberger, Suneel Kamath, Porscha Johnson Williams, Terence Rhodes, Howard McLeod, Daniel Rotroff
Read the Full Article on JCO Precision Oncology
Read more posts on OncoDaily.